Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Sheldon Mauer

Pediatric Nephrology Minneapolis, MN Medical Doctor

NPI 1174607436 CMS profile 8228

University Of Minnesota Physicians, 516 Delaware St. Se, Room 4-100, Minneapolis, MN 55455

Open in the dashboard

General payments

$102,635

60 records reported · program years 2019–2024

Research payments

$1,719

Paid to them · 3 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Sheldon Mauer of Minneapolis, MN is reported in the CMS Open Payments database as having received $102,635 across 60 general payments and $1,719 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pediatric Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $2,548 1
2023 General $1,800 1
2023 Research $1,250 1
2022 General $48,397 8
2021 General $10,260 4
2020 General $10,366 13
2019 General $29,265 33
2019 Research $469 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sheldon Mauer
  • Pediatric Nephrology median
  • Middle half of Pediatric Nephrology
  • National median

In program year 2025, general payments to Sheldon Mauer were reported at $0. Among 327 Pediatric Nephrology profiles paid that year, the median was $131 and the middle half received between $47 and $474.

Show as a table
Year Sheldon Mauer Pediatric Nephrology median Middle half National median
2019 $29,265 $123 $48–$353 $163
2020 $10,366 $146 $24–$2,251 $114
2021 $10,260 $138 $26–$1,371 $132
2022 $48,397 $93 $25–$427 $149
2023 $1,800 $105 $30–$375 $160
2024 $2,548 $123 $40–$481 $164
2025 $0 $131 $47–$474 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Genzyme Corporation $65,712 51 payments
  2. Chiesi USA, Inc. $27,120 2 payments
  3. Amicus Therapeutics, Inc. $5,025 1 payment
  4. Sanofi US Services Inc. $2,542 2 payments
  5. Sanofi-Aventis U.S. LLC $1,297 2 payments
  6. Novo Nordisk Inc $540 1 payment
  7. Bioverativ Therapeutics Inc. $400 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $86,166 25 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,363 7 payments
  3. Travel and Lodging $1,390 11 payments
  4. Food and Beverage $716 17 payments
Products named General payments · program years 2019–2024
  1. FABRAZYME Genetic Disease $32,175 19 payments
  2. FABRAZYME Rare Disease Genetics $18,166 24 payments
  3. DISEASE STATE $5,523 6 payments
  4. GZ402671 $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Genzyme Corporation $1,719 3 payments

Records

63 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Nephrology in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record